chapter 38 respiratory drugs - week 4 Flashcards
diseases of the lower respirotary tract
Chronic obstructive pulmonary disease
Asthma (persistent and present most of the time despite treatment)
Formerly known as emphysema and chronic bronchitis
bronchial asthma
- Recurrent and reversible shortness of breath
- Occurs when the airways of the lungs become narrow as a result of:
- Bronchospasms
- Inflammation of the bronchial mucosa
- Edema of the bronchial mucosa
- Production of viscous mucus
- The alveolar ducts and alveoli remain open, but airflow to them is obstructed
Symptoms
Wheezing
Difficulty breathing
asthma
A sudden and dramatic onset is referred to as an asthma attack.
Prolonged asthma attack that does not respond to typical drug therapy is known as status asthmaticus.
staus asthmaticus
Prolonged asthma attack that does not respond to typical drug therapy
May last several minutes to hours
Medical emergency
copd (chronic obstrictive pulmonary disease)
Progressive respiratory disorder
Characterized by chronic airflow limitation, systematic manifestations, and significant comorbidities
chronic bronchitis`
Presence of cough and sputum for at least 3 months in each of 2 consecutive years
Separate disease from chronic obstructive pulmonary disease
broncho dilators
Bronchodilators
* Relax bronchial smooth muscle, which causes dilation of the bronchi and bronchioles that are narrowed as a result of the disease process
* Three classes: β-adrenergic agonists, anticholinergics, and xanthine derivatives
Short-acting ß-agonist (SABA) inhalers
salbutamol (Ventolin®)
Terbutaline sulphate (Bricanyl®)
Long-acting ß-agonist (LABA) inhalers
formoterol (Foradil®, Oxeze®)
salmeterol (Serevent®)
Long-acting ß-agonist and glucocorticoid steroid combination inhaler
budesonide/formoterol fumarate dihydrate (Symbicort®)
Use as a reliever or rescue treatment for moderate to severe asthma when symptoms worsen
bronchodilators: ß-Adrenergic Agonists
Used during acute phase of asthmatic attacks
Quickly reduce airway constriction and restore normal airflow
Agonists, or stimulators, of the adrenergic receptors in the sympathetic nervous system
Sympathomimetics
ß-Adrenergic Agonists: Mechanism of Action
Begins at the specific receptor stimulated
Ends with dilation of the airways
Activation of ß2-receptors activates cyclic adenosine monophosphate, which relaxes smooth muscle in the airway and results in bronchial dilation and increased airflow.
ß-Adrenergic Agonists: Indications
Relief of bronchospasm related to asthma, chronic obstructive pulmonary disease (COPD), and other pulmonary diseases
Used in treatment and prevention of acute attacks
Used in hypotension and shock
ß-Adrenergic Agonists: Contraindications
Known drug allergy
Uncontrolled cardiac dysrhythmias
High risk of stroke (because of the vasoconstrictive drug action)
ß-Adrenergic Agonists: Adverse Effects
α and ß (epinephrine)
Insomnia
Restlessness
Anorexia
Vascular headache
Hyperglycemia
Tremor
Cardiac stimulation
ß1 and ß2
Cardiac stimulation, tachycardia
Tremor
Anginal pain
Vascular headache
ß2 (salbutamol)
Hypotension or hypertension
Vascular headache
Tremor
ß-Adrenergic Agonists: Interactions
Diminished bronchodilation when nonselective ß-blockers are used with the ß-agonist bronchodilators
Monoamine oxidase inhibitors
Sympathomimetics
Monitor patients with diabetes; an increase in blood glucose levels can occur.
ß-Adrenergic Agonists: Salbutamol Sulphate (Ventolin®)
Short-acting ß2-specific bronchodilating ß-agonist
Most commonly used drug in this class
Must not be used too frequently
Oral, parenteral, and inhalational use
Inhalational dosage forms include metered-dose inhalers as well as solutions for inhalation (aerosol nebulizers).
ß-Adrenergic Agonists: Salmeterol (Serevent®)
Long-acting ß2-agonist bronchodilator
Never to be used alone but in combination with an inhaled glucocorticoid steroid
Used for the maintenance treatment of asthma and COPD; salmeterol maximum daily dose (one puff twice daily) should not be exceeded.
Anticholinergics: Mechanism of Action
Acetylcholine (ACh) causes bronchial constriction and narrowing of the airways.
Anticholinergics bind to the ACh receptors, preventing ACh from binding.
Result: bronchoconstriction is prevented, airways dilate
Anticholinergics: Mechanism of Action
Acetylcholine (ACh) causes bronchial constriction and narrowing of the airways.
Anticholinergics bind to the ACh receptors, preventing ACh from binding.
Result: bronchoconstriction is prevented, airways dilate
Anticholinergics
ipratropium (Atrovent®), tiotropium bromide monohydrate (Spiriva®)
Indirectly cause airway relaxation and dilation
Help reduce secretions in COPD patients
Indications: prevention of the bronchospasm associated with COPD; not for the management of acute symptoms